Posted by Michael Wonder on 25 Aug 2018
Multiple myeloma meeting outcome statement
24 August 2018 - The outcome statement for the multiple myeloma stakeholder meeting held on 23 May 2018 is now available.
The PBAC Chair acknowledged that changes to the current PBS listings for treatments for multiple myeloma will require advocacy from clinicians and patient groups, and co- operation from sponsors with the PBAC and the Department, and this stakeholder meeting provides an important forum to discuss ways forward.
The PBAC Chair noted that a simplified PBS listing of ‘multiple myeloma’ for bortezomib and lenalidomide may address many aspects of these priorities. This may also more readily allow access to combination with new therapies, such as daratumumab, as they become available. However, price reductions would be needed in order for PBAC to be able to recommend the implementation of this change.
